Financial & Business, OEM News

J&J MedTech Completes $1.7B Deal for V-Wave

V-Wave’s Ventura interatrial shunt targets heart failure with reduced ejection fraction (HFrEF).

Author Image

By: Sam Brusco

Associate Editor

Johnson & Johnson has completed its acquisition of V-Wave, a privately-held company that develops innovative treatment options for heart failure patients. V-Wave will now operate as part of Johnson & Johnson MedTech.
 
The up to $1.7 billion deal was announced in late August of this year. V-Wave complements J&J MedTech’s cardiovascular portfolio, which already contains platforms that address coronary artery disease and peripheral artery disease, heart recovery, and atrial fibrillation.
 
J&J also said the transaction will deepen its relationships with structural interventional cardiologists and heart failure specialists.
 
V-Wave’s cardiovascular implant technology targets heart failure with reduced ejection fraction (HFrEF), a condition where the heart muscle cannot sufficiently pump blood-containing oxygen and nutrients to the body. The company’s Ventura interatrial shunt (IAS) decreases elevated left atrial pressure seen in congestive heart failure by creating a shunt between the left and right atrium.
 
The Ventura IAS is implanted in the heart in a minimally invasive, catheter-based procedure. J&J believes it could fill a significant treatment gap between guideline-directed medical therapies (GDMT) as a first-line therapy and invasive cardiac replacement therapies like left ventricular assist devices (LVADs) and heart transplantation.
 
Johnson & Johnson expects the transaction to dilute adjusted earnings per share (EPS) by approximately $0.24 in 2024 and approximately $0.06 in 2025.
 
“We’re excited to officially welcome V-Wave to Johnson & Johnson MedTech,” said Tim Schmid, executive VP and worldwide chairman of Johnson & Johnson MedTech. “V-Wave’s novel implantable device, the Ventura Interatrial Shunt, offers tremendous promise for patients experiencing heart failure with reduced ejection fraction. This technology has the potential to be the first device of its kind to market. We look forward to working with the talented V-Wave team to bring this transformative innovation to patients.”
 
Earlier this year, J&J closed its $13.1 billion deal for Shockwave Medical, maker of the first, only intravascular lithotripsy (IVL) platform for coronary artery disease (CAD) and peripheral artery disease (PAD).

Keep Up With Our Content. Subscribe To Medical Product Outsourcing Newsletters